Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1

Biochemical Pharmacology

Volumn 61, Issue 3, 2001, Pages 299-310

  Facompre, Michael ^a   Goossens, Jean François ^b   Bailly, Christian ^a  

^a INSERM   (France)

^b UNIV LILLE   (France)

Author keywords

Apoptosis; Caspases; Cell cycle; DNA fragmentation; Topoisomerases

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; CALCIUM; CAMPTOTHECIN; CASPASE 3; CASPASE 8; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; PROTEINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE G1 PHASE; CELL PH; CELL STRAIN HL 60; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CLEAVAGE; DNA DEGRADATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA; MEMBRANE POTENTIAL; NICK END LABELING; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CARBAZOLES; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE; CELL NUCLEUS; CYTOPLASM; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE I; ENZYME ACTIVATION; GLUCOSIDES; GLYCOSYLATION; HL-60 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 0035254661     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00553-0     Document Type: Article

References (59)

1. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopy ranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): Its potent antitumor activities in mice
2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopy ranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity
3. Phase I and pharmacology study of 5-day infusion of NB-506
4. New chemotherapeutic agents for the treatment of non-small cell lung cancer
5. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives
6. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110
7. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin
8. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding and topoisomerase I inhibition activities
9. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents
10. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin
11. Calories from carbohydrates: Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition
12. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles
13. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB
14. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I
15. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: Stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity
16. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells
17. Cell death induced by topoisomerase-targeted drugs: More questions than answers
18. Synthesis of NB-506, a new anticancer agent
19. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays
20. Intracellular ion activities and membrane transport in parietal cells measured with fluorescent dyes
21. Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells
22. 2+ indicators with greatly improved fluorescence properties
23. ++] with fluorescent indicators
24. Identification of dying cells - In situ staining
25. The mitochondrial permeability transition
26. Mitochondrial control of apoptosis
27. The mitochondrial death/life regulator in apoptosis and necrosis
28. 2+ are not required to trigger apoptosis in human leukemia cells
29. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase
30. Proteolytic activities that mediate apoptosis
31. Caspases: The proteases of the apoptotic pathway
32. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: Effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases
33. Substrate specificity of caspase family proteases
34. Caspases and caspase inhibitors
35. Purification and catalytic properties of human caspase family members
36. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase
37. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
38. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
39. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens
40. Pro-caspase-3 is a major physiologic target of caspase-8
41. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
42. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c
43. A biochemical hallmark of apoptosis: Internucleosomal degradation of the genome
44. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
45. Quercetin and anti-CD95 (Fas/Apo1) enhance apoptosis in HPB-ALL cell line
46. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
47. Etoposide-induced apoptosis is not associated with the Fas pathway in acute myeloblastic leukemia cells
48. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors
49. The role of Fas in apoptosis induced by anticancer drugs
50. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells
51. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells
52. The HL-60 promyelocytic leukemia cell line: Proliferation, differentiation and cellular oncogene expression
53. Mitochondrial release of caspase-2 and -9 during the apoptotic process
54. The central executioner of apoptosis: Multiple links between protease activation and mitochondria in Fas/Apo-1/CD95- and ceramide-induced apoptosis
55. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
56. Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells
57. Role of intracellular pH in proliferation, transformation, and apoptosis
58. Differential effect of metabolic inhibitors on cellular and mitochondrial uptake of organic cations in rat liver
59. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives